Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

doi:10.1016/j.cell.2021.02.037

. 2021 Apr 29;184(9):2348-2361.e6.

doi: 10.1016/j.cell.2021.02.037. Epub 2021 Feb 23.

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Daming Zhou¹, Wanwisa Dejnirattisai², Piyada Supasa², Chang Liu³, Alexander J Mentzer⁴, Helen M Ginn⁵, Yuguang Zhao¹, Helen M E Duyvesteyn¹, Aekkachai Tuekprakhon², Rungtiwa Nutalai², Beibei Wang², Guido C Paesen¹, Cesar Lopez-Camacho², Jose Slon-Campos², Bassam Hallis⁶, Naomi Coombes⁶, Kevin Bewley⁶, Sue Charlton⁶, Thomas S Walter², Donal Skelly⁷, Sheila F Lumley⁸, Christina Dold⁹, Robert Levin¹⁰, Tao Dong¹¹, Andrew J Pollard⁹, Julian C Knight¹², Derrick Crook¹³, Teresa Lambe¹⁴, Elizabeth Clutterbuck⁹, Sagida Bibi⁹, Amy Flaxman¹⁴, Mustapha Bittaye¹⁴, Sandra Belij-Rammerstorfer¹⁴, Sarah Gilbert¹⁴, William James¹⁵, Miles W Carroll¹⁶, Paul Klenerman¹⁷, Eleanor Barnes¹⁷, Susanna J Dunachie¹⁸, Elizabeth E Fry¹, Juthathip Mongkolsapaya¹⁹, Jingshan Ren²⁰, David I Stuart²¹, Gavin R Screaton²²

Affiliations

¹ Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
² Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
³ Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS), Oxford Institute (COI), University of Oxford, Oxford, UK.
⁴ Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
⁵ Instruct-ERIC, Oxford House, Parkway Court, John Smith Drive, Oxford, UK.
⁶ National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
⁷ Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
⁸ Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
⁹ NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
¹⁰ Worthing Hospital, Worthing, UK.
¹¹ Chinese Academy of Medical Science (CAMS), Oxford Institute (COI), University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
¹² Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS), Oxford Institute (COI), University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
¹³ Nuffield Department of Medicine, University of Oxford, Oxford, UK.
¹⁴ Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
¹⁵ Sir William Dunn School of Pathology University of Oxford, Oxford, UK.
¹⁶ Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
¹⁷ Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
¹⁸ Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Centre For Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand.
¹⁹ Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS), Oxford Institute (COI), University of Oxford, Oxford, UK; Siriraj Center of Research Excellence in Dengue & Emerging Pathogens, Dean Office for Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand. Electronic address: jmongkol@well.ox.ac.uk.
²⁰ Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK. Electronic address: ren@strubi.ox.ac.uk.
²¹ Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK; Chinese Academy of Medical Science (CAMS), Oxford Institute (COI), University of Oxford, Oxford, UK; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK; Instruct-ERIC, Oxford House, Parkway Court, John Smith Drive, Oxford, UK. Electronic address: dave.stuart@diamond.ac.uk.
²² Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS), Oxford Institute (COI), University of Oxford, Oxford, UK. Electronic address: gavin.screaton@medsci.ox.ac.uk.

PMID: 33730597
PMCID: PMC7901269
DOI: 10.1016/j.cell.2021.02.037

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Daming Zhou et al. Cell. 2021.

. 2021 Apr 29;184(9):2348-2361.e6.

doi: 10.1016/j.cell.2021.02.037. Epub 2021 Feb 23.

Authors

Affiliations

¹ Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
² Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
³ Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS), Oxford Institute (COI), University of Oxford, Oxford, UK.
⁴ Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
⁵ Instruct-ERIC, Oxford House, Parkway Court, John Smith Drive, Oxford, UK.
⁶ National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
⁷ Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
⁸ Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
⁹ NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
¹⁰ Worthing Hospital, Worthing, UK.
¹¹ Chinese Academy of Medical Science (CAMS), Oxford Institute (COI), University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
¹² Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS), Oxford Institute (COI), University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
¹³ Nuffield Department of Medicine, University of Oxford, Oxford, UK.
¹⁴ Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
¹⁵ Sir William Dunn School of Pathology University of Oxford, Oxford, UK.
¹⁶ Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
¹⁷ Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
¹⁸ Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Centre For Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand.
¹⁹ Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS), Oxford Institute (COI), University of Oxford, Oxford, UK; Siriraj Center of Research Excellence in Dengue & Emerging Pathogens, Dean Office for Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand. Electronic address: jmongkol@well.ox.ac.uk.
²⁰ Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK. Electronic address: ren@strubi.ox.ac.uk.
²¹ Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK; Chinese Academy of Medical Science (CAMS), Oxford Institute (COI), University of Oxford, Oxford, UK; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK; Instruct-ERIC, Oxford House, Parkway Court, John Smith Drive, Oxford, UK. Electronic address: dave.stuart@diamond.ac.uk.
²² Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS), Oxford Institute (COI), University of Oxford, Oxford, UK. Electronic address: gavin.screaton@medsci.ox.ac.uk.

PMID: 33730597
PMCID: PMC7901269
DOI: 10.1016/j.cell.2021.02.037

Abstract

The race to produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began when the first sequence was published, and this forms the basis for vaccines currently deployed globally. Independent lineages of SARS-CoV-2 have recently been reported: UK, B.1.1.7; South Africa, B.1.351; and Brazil, P.1. These variants have multiple changes in the immunodominant spike protein that facilitates viral cell entry via the angiotensin-converting enzyme-2 (ACE2) receptor. Mutations in the receptor recognition site on the spike are of great concern for their potential for immune escape. Here, we describe a structure-function analysis of B.1.351 using a large cohort of convalescent and vaccinee serum samples. The receptor-binding domain mutations provide tighter ACE2 binding and widespread escape from monoclonal antibody neutralization largely driven by E484K, although K417N and N501Y act together against some important antibody classes. In a number of cases, it would appear that convalescent and some vaccine serum offers limited protection against this variant.

Keywords: ACE2; B.1.351; SARS-CoV-2; South Africa; antibody; escape; neutralization; receptor-binding domain; vaccine; variant.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests G.R.S. sits on the GSK Vaccines Scientific Advisory Board. Oxford University holds intellectual property related to the Oxford-AstraZeneca vaccine. A.J.P. is Chair of UK Department Health and Social Care’s (DHSC) Joint Committee on Vaccination & Immunisation (JCVI), but does not participate in the JCVI COVID-19 committee, and is a member of the WHO’s SAGE. The views expressed in this article do not necessarily represent the views of DHSC, JCVI, or WHO. The University of Oxford has entered into a partnership with AstraZeneca on coronavirus vaccine development. The University of Oxford has protected intellectual property disclosed in this publication.

Figures

**Figure 1**
Evolution of B.1.351 variant (A and B) Sliding 7-day window depicting proportion of sequences with wild-type (gray), 501Y mutation only (green), NTD deletion only (purple), and double-mutation variant (black) for (A) sequences selected containing UK, NTD deletion 69–70 and (B) South Africa, NTD deletion 241–243. (C) Structure plot showing distribution of mutations of South African variant sequences as defined by N501Y and deletion 241–243; point mutations are marked in yellow and the deletions in dark gray. Structure plots use spike protein structure (original frame from PDB: 6ZWV) where modeled, and models were extended in Coot for missing loops. (D) Positions of major changes in the spike protein are highlighted in the NTD and RBD. (E) Positions of the K417N, E484K, and N501Y (yellow) mutations within the ACE2 interaction surface (dark green) of RBD. The view is chosen for clarity and is related to that shown in (C) by a 45° rotation around the axis coming out of the page (to make the RBD upright compared with C) and an almost 180° rotation around the long axis of the RBD domain. (F) A linear representation of B.1.351 spike with changes marked on. Note the strain used in this report does not have L18F and R246I mutations.

**Figure 2**
Neutralization of Victoria and B.1.351 viruses by convalescent plasma Plasma was collected in the UK before June 2020, during the first wave of SARS-CoV-2, in the early convalescent phase 4–9 weeks following admission to hospital. (A) FRNT assays comparing neutralization of Victoria (orange) and B.1.351 (green) (n = 34). (B) Neutralization assays of Victoria and B.1.351 with plasma obtained from patients suffering B.1.1.7 infection at the indicated times following infection. (C and D) Comparison of FRNT₅₀ titers between B.1.351 and Victoria strains for convalescent and B.1.1.7 plasma, respectively. The Wilcoxon matched-pairs signed rank sum test was used for the analysis and two-tailed p values were calculated; geometric mean values are indicated above each column. The data underpinning the Victoria neutralization curves have been previously reported (Supasa et al., 2021). Individual FRNT₅₀ values are shown in Table S1.

**Figure 3**
Neutralization of B.1.351 by vaccine serum (A and B) Neutralization FRNT curves for Victoria and B.1.351 strains by (A) 25 sera taken 7–17 days following the second dose of the Pfizer-BioNTech vaccine and (B) 25 sera taken 14 or 28 days following the second dose of the Oxford-AstraZeneca vaccine. (C and D) Comparison of FRNT₅₀ titers between B.1.351 and Victoria strains for the Pfizer-BioNTech and Oxford-AstraZeneca vaccines, respectively. The Wilcoxon matched-pairs signed rank sum test was used for the analysis and two-tailed p values were calculated; geometric mean values are indicated above each column. The data underpinning the Victoria neutralization curves have been previously reported (Supasa et al., 2021). Individual FRNT₅₀ values are shown in Table S2. See also Figure S1.

**Figure S1**
Neutralization of Victoria and B.1.351 by serum collected before vaccination, related to Figure 3 Neutralization for Victoria and B.1.351 strains by 50 sera taken at day zero before the first dose of AstraZeneca vaccine. All sera were assayed in three-fold dilutions at 1:20 and 1:60 for the final dilutions.

**Figure 4**
Neutralization by potent mAbs (A) Neutralization curves for Victoria and B.1.351 using 22 human monoclonal antibodies (mAbs). (B) Neutralization curves of Victoria and B.1.351 strains using mAb pairs from Regeneron and AstraZeneca. The data underpinning the Victoria neutralization curves have been previously reported (Supasa et al., 2021). Individual FRNT₅₀ values are shown in Table S3.

**Figure 5**
Interactions of mutation site residues with a selection of RBD-binding mAbs (A–D) Interactions of (A) Fab 88 with K417 and E484 of the RBD (PDB: 7BEL), (B) 150 with N501 and K417 (PDB: 7BEI), (C) 253 has no contact with any of the three mutation sites (PDB: 7BEN), and (D) Fab 384 with only E484 (PDB: 7BEP). (E) Structures of IGHV3-51 and IGHV3-66 Fabs by overlapping the Cα backbones of the RBD. (F) Interactions of K417 with CB6 Fab (PDB: 7C01 [Wajnberg et al., 2020]). (G) The K417N mutation is modeled in the RBD/CB6 complex. In (A) to (G), the Fab light chain, heavy chain, and RBD are in blue, salmon, and gray, respectively. Cα backbones are drawn in thinner sticks and side chains in thicker sticks. Contacts (≤4 Å) are shown as yellow dashed lines and hydrogen bonds and salt bridges as blue dashed lines. (H and I) Positions of mutations and the deletion in the spike NTD of the B.1.351 variant relative to the bound antibodies (H) 159 (PDB: 7NDC) and (I) 4A8 (PDB: 7C2L); the 242–244 deletion would be predicted to disrupt the interaction of 159 and 4A4. The heavy chain and light chain variable domains (Vh and Vl) of the Fabs are shown as salmon and blue surfaces, respectively, and the NTD as gray sticks. The mutation sites are drawn as green spheres and deletions as magenta spheres.

**Figure 6**
Antibody RBD interaction and structural modeling (A and B) BLI plots showing a titration series of binding to ACE2 (see STAR Methods) for (A) Wuhan RBD and (B) K417N, E484K, and N501Y B.1.351 RBD. Note the much slower off-rate for B.1.351. (C and D) K_D of RBD/mAb interaction measured by BLI for WT Wuhan RBD (left dots) and K417N, E484K, and N501Y B.1.351 RBD (right dots). (E) Epitopes as defined by the clustering of mAbs on the RBD (gray). (F) BLI data mapped onto the RBD using the method described in (Dejnirattisai et al., 2021). Front and back views of the RBD are depicted with the spheres representing the antibody binding sites colored according to the ratio (K_DB.1.351/K_DWuhan). For white, the ratio is 1; for red, it is <0.1 (i.e., at least 10-fold reduction). Black dots refer to mapped antibodies not included in this analysis; dark green to RBD ACE2-binding surface; and yellow to mutated K417N, E484K, and N501Y. (G) As for the left pair, but colored according to the ratio of neutralization titers (half-maximal inhibitory concentration [IC₅₀]B.1.351/[IC₅₀]Victoria). For white, the ratio is 1; for red, it is <0.01 (i.e., at least 100-fold reduction). Note the strong concordance between the two effects, with 269 being the most strongly affected. The nearby pink antibodies are mainly the IGHV3-53 and IGHV3-66 antibodies.

See this image and copyright information in PMC

Cited by

Statistical Challenges in Tracking the Evolution of SARS-CoV-2.
Cappello L, Kim J, Liu S, Palacios JA. Cappello L, et al. Stat Sci. 2022 May;37(2):162-182. doi: 10.1214/22-sts853. Epub 2022 May 16. Stat Sci. 2022. PMID: 36034090 Free PMC article.
mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition.
Röltgen K, Nielsen SCA, Arunachalam PS, Yang F, Hoh RA, Wirz OF, Lee AS, Gao F, Mallajosyula V, Li C, Haraguchi E, Shoura MJ, Wilbur JL, Wohlstadter JN, Davis MM, Pinsky BA, Sigal GB, Pulendran B, Nadeau KC, Boyd SD. Röltgen K, et al. medRxiv [Preprint]. 2021 Apr 7:2021.04.05.21254952. doi: 10.1101/2021.04.05.21254952. medRxiv. 2021. PMID: 33851181 Free PMC article. Preprint.
Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination.
Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, Gouma S, Hicks P, Meng W, Rosenfeld AM, Dysinger S, Lundgreen KA, Kuri-Cervantes L, Adamski S, Hicks A, Korte S, Oldridge DA, Baxter AE, Giles JR, Weirick ME, McAllister CM, Dougherty J, Long S, D'Andrea K, Hamilton JT, Betts MR, Luning Prak ET, Bates P, Hensley SE, Greenplate AR, Wherry EJ. Goel RR, et al. Sci Immunol. 2021 Apr 15;6(58):eabi6950. doi: 10.1126/sciimmunol.abi6950. Sci Immunol. 2021. PMID: 33858945 Free PMC article.
Surveillance for SARS-CoV-2 variants of concern in the Australian context.
Andersson P, Sherry NL, Howden BP. Andersson P, et al. Med J Aust. 2021 Jun;214(11):500-502.e1. doi: 10.5694/mja2.51105. Epub 2021 May 31. Med J Aust. 2021. PMID: 34060079 Free PMC article. No abstract available.
SARS-CoV-2 mRNA vaccination elicits broad and potent Fc effector functions to VOCs in vulnerable populations.
Hederman AP, Natarajan H, Wiener JA, Wright PF, Bloch EM, Tobian AAR, Redd AD, Blankson JN, Rottenstreich A, Zarbiv G, Wolf D, Goetghebuer T, Marchant A, Ackerman ME. Hederman AP, et al. medRxiv [Preprint]. 2022 Sep 18:2022.09.15.22280000. doi: 10.1101/2022.09.15.22280000. medRxiv. 2022. Update in: Nat Commun. 2023 Aug 24;14(1):5171. doi: 10.1038/s41467-023-40960-0 PMID: 36172122 Free PMC article. Updated. Preprint.

See all "Cited by" articles

References

1. Andreano E., Piccini G., Licastro D., Casalino L., Johnson N.V., Paciello I., Monego S.D., Pantano E., Manganaro N., Manenti A. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv. 2020 doi: 10.1101/2020.12.28.424451. - DOI - PMC - PubMed
1. Aricescu A.R., Lu W., Jones E.Y. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D Biol Crystallogr. 2006;62:1243–1250. - PubMed
1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., COVE Study Group Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. - PMC - PubMed
1. Baum A., Fulton B.O., Wloga E., Copin R., Pascal K.E., Russo V., Giordano S., Lanza K., Negron N., Ni M. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014–1018. - PMC - PubMed
1. Caly L., Druce J., Roberts J., Bond K., Tran T., Kostecki R., Yoga Y., Naughton W., Taiaroa G., Seemann T. Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med. J. Aust. 2020;212:459–462. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information
Molecular Biology Databases
- BioCyc
Miscellaneous
- NCI CPTAC Assay Portal

[1] Andreano E., Piccini G., Licastro D., Casalino L., Johnson N.V., Paciello I., Monego S.D., Pantano E., Manganaro N., Manenti A. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv. 2020 doi: 10.1101/2020.12.28.424451. - DOI - PMC - PubMed

[2] Andreano E., Piccini G., Licastro D., Casalino L., Johnson N.V., Paciello I., Monego S.D., Pantano E., Manganaro N., Manenti A. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv. 2020 doi: 10.1101/2020.12.28.424451. - DOI - PMC - PubMed

[3] Aricescu A.R., Lu W., Jones E.Y. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D Biol Crystallogr. 2006;62:1243–1250. - PubMed

[4] Aricescu A.R., Lu W., Jones E.Y. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D Biol Crystallogr. 2006;62:1243–1250. - PubMed

[5] Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., COVE Study Group Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. - PMC - PubMed

[6] Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., COVE Study Group Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. - PMC - PubMed

[7] Baum A., Fulton B.O., Wloga E., Copin R., Pascal K.E., Russo V., Giordano S., Lanza K., Negron N., Ni M. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014–1018. - PMC - PubMed

[8] Baum A., Fulton B.O., Wloga E., Copin R., Pascal K.E., Russo V., Giordano S., Lanza K., Negron N., Ni M. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014–1018. - PMC - PubMed

[9] Caly L., Druce J., Roberts J., Bond K., Tran T., Kostecki R., Yoga Y., Naughton W., Taiaroa G., Seemann T. Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med. J. Aust. 2020;212:459–462. - PMC - PubMed

[10] Caly L., Druce J., Roberts J., Bond K., Tran T., Kostecki R., Yoga Y., Naughton W., Taiaroa G., Seemann T. Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med. J. Aust. 2020;212:459–462. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Affiliations

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Miscellaneous

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Miscellaneous